	US 12,453,768 B2
	Vaccines for in vivo expression of nucleic acids and methods of using the same
Thomas E. Wagner, Greenville, SC (US)
Assigned to ORBIS HEALTH SOLUTIONS, LLC, Greenville, SC (US)
Filed by ORBIS HEALTH SOLUTIONS, LLC, Greenville, SC (US)
Filed on Dec. 20, 2022, as Appl. No. 18/085,478.
Application 18/085,478 is a continuation of application No. 16/909,311, filed on Jun. 23, 2020, granted, now 11,529,414.
Prior Publication US 2025/0009875 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/385 (2006.01); A61K 39/00 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/385 (2013.01) [A61K 39/215 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/6006 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20071 (2013.01)]

16 Claims

1. A vaccine comprising: (i) a yeast cell wall particle (YCWP) that is surface-modified with polyethyleneimine (PEI), (ii) a lysosome-evading component attached to the YCWP, and (iii) a deoxyribonucleic acid (DNA) sequence encoding an immunogenic peptide from a virus or bacteria, wherein the nucleic acid is attached to the YCWP via a complex formed between the PEI and the nucleic acid, wherein intradermal administration of the vaccine to a human subject elicits an immunogenic response.